Patents by Inventor Laszlo Tanko

Laszlo Tanko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of Improving or Accelerating Physical Recovery After Surgery for Hip Fracture
    Publication number: 20180230221
    Abstract: The disclosure relates to novel uses and regimens for accelerating/improving physical recovery in a patient with disuse atrophy triggered by reduced mobility due to a hip fracture and consequent major surgery, which employ a therapeutically effective amount of a myostatin antagonist, e.g., a myostatin binding molecule, e.g., a myostatin antibody or an ActRII receptor binding molecule, an ActRII receptor antibody, such as the bimagrumab antibody.
    Type: Application
    Filed: April 10, 2018
    Publication date: August 16, 2018
    Inventors: Laszlo Tanko, Dimitris PAPANICOLAOU, Jörg GOLDHAHN
  • Administration of bimagrumab for improving muscle mass and function after hip fracture surgery
    Patent number: 9969806
    Abstract: The disclosure relates to uses and regimens for accelerating/improving physical recovery in a patient with disuse atrophy triggered by reduced mobility due to a hip fracture and consequent major surgery, which employ a therapeutically effective amount of a myostatin antagonist, e.g., a myostatin binding molecule, e.g., a myostatin antibody or an ActRII receptor binding molecule, an ActRII receptor antibody, such as the bimagrumab antibody.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: May 15, 2018
    Assignee: Novartis AG
    Inventors: Laszlo Tanko, Dimitris Papanicolaou, Jörg Goldhahn
  • Methods of Improving or Accelerating Physical Recovery After Surgery for Hip Fracture
    Publication number: 20170029513
    Abstract: The disclosure relates to uses and regimens for accelerating/improving physical recovery in a patient with disuse atrophy triggered by reduced mobility due to a hip fracture and consequent major surgery, which employ a therapeutically effective amount of a myostatin antagonist, e.g., a myostatin binding molecule, e.g., a myostatin antibody or an ActRII receptor binding molecule, an ActRII receptor antibody, such as the bimagrumab antibody.
    Type: Application
    Filed: April 24, 2015
    Publication date: February 2, 2017
    Applicant: Novartis AG
    Inventors: Laszlo Tanko, Dimitris PAPANICOLAOU, Jörg GOLDHAHN